{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:10:05Z","timestamp":1747660205283,"version":"3.40.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00415-025-13114-z","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T11:06:48Z","timestamp":1746356808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up"],"prefix":"10.1007","volume":"272","clinical-trial-number":[{"clinical-trial-number":"nct02644044","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hadar","family":"Kolb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Shachaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Fainberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Golan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Regev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifat","family":"Vigiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Gadoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Kestenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurit","family":"Omer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Shopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa L.","family":"Ash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moran","family":"Artzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Ben Bashat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orna","family":"Aizenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-7900","authenticated-orcid":false,"given":"Arnon","family":"Karni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"13114_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple SCLEROSIS. N Engl J Med 378:169\u2013180","journal-title":"N Engl J Med"},{"key":"13114_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","volume":"94","author":"FD Lublin","year":"2020","unstructured":"Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ (2020) The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94:1088\u20131092","journal-title":"Neurology"},{"issue":"8","key":"13114_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8):765\u2013779","journal-title":"JAMA"},{"issue":"10422","key":"13114_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B (2024) Multiple sclerosis. Lancet 403(10422):183\u2013202","journal-title":"Lancet"},{"issue":"9350","key":"13114_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"HP Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, K\u00f6nig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018\u201325","journal-title":"Lancet"},{"key":"13114_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209\u2013220","journal-title":"N Engl J Med"},{"key":"13114_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstr\u00f6m E, Dahlke F (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263\u20131273","journal-title":"Lancet"},{"issue":"3","key":"13114_CR8","first-page":"116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 9(3):116","journal-title":"Front Immunol"},{"key":"13114_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","volume":"23","author":"BN Cronstein","year":"1997","unstructured":"Cronstein BN (1997) The mechanism of action of methotrexate. Rheum Dis Clin North Am 23:739\u2013755","journal-title":"Rheum Dis Clin North Am"},{"key":"13114_CR10","first-page":"703","volume":"61","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA, Dedrick RL (1977) Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703\u2013708","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"13114_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16(3):145\u2013154","journal-title":"Nat Rev Rheumatol"},{"key":"13114_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.410370108","volume":"37","author":"DE Goodkin","year":"1995","unstructured":"Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30\u201340","journal-title":"Ann Neurol"},{"key":"13114_CR13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/jnnp.56.11.1217","volume":"56","author":"RD Currier","year":"1993","unstructured":"Currier RD, Haerer AF, Meydrech EF (1993) Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 56:1217\u20131218","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13114_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s100720170026","volume":"22","author":"A Lugaresi","year":"2001","unstructured":"Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, De Luca G, Iarlori C, Gambi D (2001) Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci 22:209\u2013210","journal-title":"Neurol Sci"},{"key":"13114_CR15","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1007\/s00415-010-5614-4","volume":"257","author":"SA Sadiq","year":"2010","unstructured":"Sadiq SA, Simon EV, Puccio LM (2010) Intrathecal methotrexate treatment in multiple sclerosis. J Neurol 257:1806\u20131811","journal-title":"J Neurol"},{"key":"13114_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419892360","author":"JW Stark","year":"2019","unstructured":"Stark JW, Josephs L, Dulak D, Clague M, Sadiq SA (2019) Safety of long-term intrathecal methotrexate in progressive forms of MS. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286419892360","journal-title":"Ther Adv Neurol Disord"},{"key":"13114_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302","journal-title":"Ann Neurol"},{"key":"13114_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.apmr.2019.08.488","volume":"101","author":"EM Sikes","year":"2020","unstructured":"Sikes EM, Cederberg KL, Sandroff BM, Bartolucci A, Motl RW (2020) Quantitative synthesis of timed 25-foot walk performance in multiple sclerosis. Arch Phys Med Rehabil 101:524\u2013534","journal-title":"Arch Phys Med Rehabil"},{"key":"13114_CR19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","volume":"25","author":"L Strober","year":"2019","unstructured":"Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG (2019) Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler 25:1781\u20131790","journal-title":"Mult Scler"},{"issue":"2","key":"13114_CR20","first-page":"189","volume":"45","author":"CF Geiser","year":"1975","unstructured":"Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E 3rd (1975) Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 45(2):189\u2013195","journal-title":"Blood"},{"issue":"4","key":"13114_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.pbb.2010.03.003","volume":"95","author":"Y Li","year":"2010","unstructured":"Li Y, Vijayanathan V, Gulinello M, Cole PD (2010) Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 95(4):428\u2013433","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"13114_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0887-8994(99)00040-5","volume":"21","author":"S Koh","year":"1999","unstructured":"Koh S, Nelson MD Jr, Kovanlikaya A, Chen LS (1999) Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 21(2):576\u2013578","journal-title":"Pediatr Neurol"},{"issue":"4","key":"13114_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/19418744221106313","volume":"12","author":"H Pang","year":"2022","unstructured":"Pang H, Chan JL, Bannykh SI, Gezalian M, Lahiri S, Toossi S, Ayodele M (2022) Intrathecal methotrexate toxicity resulting in brain death due to generalized cerebral edema case report. Neurohospitalist 12(4):697\u2013701","journal-title":"Neurohospitalist"},{"issue":"3","key":"13114_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS, ORATORIO Clinical Investigators (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"issue":"10127","key":"13114_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstr\u00f6m E, Dahlke F, EXPAND Clinical Investigators (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263\u20131273","journal-title":"Lancet"},{"key":"13114_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089\u20131104","journal-title":"Brain"},{"issue":"2","key":"13114_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/08880018809031261","volume":"5","author":"RJ Lippens","year":"1988","unstructured":"Lippens RJ, Winograd B (1988) Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 5(2):115\u2013124","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"13114_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 86(3):301\u2013307","journal-title":"Joint Bone Spine"},{"key":"13114_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145\u2013154","journal-title":"Nat Rev Rheumatol"},{"key":"13114_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnmol.2013.00034","volume":"6","author":"AM Mueller","year":"2013","unstructured":"Mueller AM, Nassery A, Conlon H, Liu X, Jun E, Yoon BH, Cristofanilli M, Sadiq SA (2013) Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice. Front Mol Neurosci 6:34","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"13114_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00839208","volume":"239","author":"R Heun","year":"1992","unstructured":"Heun R, Sliwka U, Ruttinger H, Schimrigk K (1992) Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study. J Neurol 239(1):31\u201335","journal-title":"J Neurol"},{"issue":"5","key":"13114_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.WNF.0000229545.81245.A4","volume":"29","author":"K Hellwig","year":"2006","unstructured":"Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N, Przuntek H, Muler T (2006) Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Clin Neuropharmacol 29(5):286\u2013291","journal-title":"Clin Neuropharmacol"},{"key":"13114_CR33","volume":"2011","author":"M Abu-Mugheisib","year":"2011","unstructured":"Abu-Mugheisib M, Benecke R, Zettl UK (2011) Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review. Mult Scler Int 2011:219049","journal-title":"Mult Scler Int"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13114-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:42:23Z","timestamp":1747658543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13114-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13114"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13114-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have no conflict of interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The Institutional Review Board (IRB) at Tel Aviv Sourasky Medical Center approved the study protocols (IRB No. 166\u201315).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants in the Phase 1 study before initiating ITMTX treatment. The IRB waived the need for informed consent in the retrospective study due to the anonymized nature of the data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"374"}}